Focused On-demand Library for Selenocysteine-specific elongation factor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P57772

UPID:

SELB_HUMAN

Alternative names:

Elongation factor sec; Eukaryotic elongation factor, selenocysteine-tRNA-specific

Alternative UPACC:

P57772; Q96HZ6

Background:

The Selenocysteine-specific elongation factor, known as Elongation factor sec or Eukaryotic elongation factor, selenocysteine-tRNA-specific, plays a pivotal role in protein synthesis. It is essential for the incorporation of selenocysteine into proteins, facilitated by its ability to bind GTP and GDP, and is directed by the UGA codon. This unique mechanism distinguishes it from the conventional EF-Tu elongation factor, underscoring its specialized function in cellular biology.

Therapeutic significance:

Understanding the role of Selenocysteine-specific elongation factor could open doors to potential therapeutic strategies. Its critical function in protein synthesis and the unique mechanism of selenocysteine incorporation highlight its potential as a target for drug discovery, aiming to modulate protein synthesis pathways for therapeutic benefits.